Jatenzo Evidence Base Graded by GRADE

What Is Jatenzo and Why Does It Need a GRADE Assessment?

Jatenzo is the only FDA-approved oral testosterone formulation in the United States designed specifically to bypass hepatic first-pass metabolism through lymphatic absorption. Older oral testosterone preparations, notably methyltestosterone, carried severe hepatotoxicity risk because they were 17-alpha alkylated. Jatenzo uses a self-emulsifying drug delivery system (SEDDS) that encapsulates testosterone undecanoate in a lipid matrix, directing absorption through intestinal lymphatics rather than the portal vein.

A GRADE assessment matters here because clinicians, payers, and patients are regularly asked to choose between injectable testosterone cypionate, transdermal gels, subcutaneous pellets, and this oral option. Without a structured evidence quality rating, those comparisons reduce to anecdote. The GRADE framework (Grading of Recommendations Assessment, Development, and Evaluation) rates evidence across four domains: risk of bias, inconsistency, indirectness, and imprecision. Each domain can downgrade certainty from High, Moderate, Low, or Very Low.

The Lymphatic Absorption Advantage

Because testosterone undecanoate is absorbed via chylomicrons into the thoracic duct, it avoids the liver on first pass. This mechanism is well-documented in pharmacokinetic studies and is the biochemical rationale behind the FDA's conclusion that Jatenzo does not carry the hepatotoxicity risk associated with 17-alpha alkylated oral androgens [1].

Why Earlier Oral Testosterone Data Cannot Be Extrapolated

Andriol (testosterone undecanoate in oleic acid, available outside the US) showed inconsistent absorption and required four daily doses. Jatenzo's SEDDS formulation produces more predictable pharmacokinetics, meaning the Andriol evidence base has limited applicability. The FDA required new dedicated trials rather than accepting bridging data from Andriol studies.

The Key Trial: Swerdloff et al. 2020

The foundational efficacy data for Jatenzo comes from Swerdloff et al., published in the Journal of Clinical Endocrinology and Metabolism in 2020. This open-label, dose-titration, phase 3 trial enrolled 166 adult men with confirmed hypogonadism (morning serum testosterone below 300 ng/dL on two separate measurements). Participants titrated through three possible dose levels (158 mg, 237 mg, or 396 mg twice daily) based on pharmacokinetic monitoring.

Primary Endpoint: Cavg in the Normal Range

The primary endpoint was the percentage of subjects whose average serum testosterone concentration (Cavg) fell within 300 to 1,050 ng/dL during the 24-hour pharmacokinetic assessment at day 90. Swerdloff et al. Reported that 87% of evaluable subjects met this endpoint [1]. Mean Cavg at day 90 was 498 ng/dL, placing the average well within mid-normal range. Secondary analyses showed that 84.6% of subjects maintained that response through the 52-week extension.

GRADE Domain Analysis: Risk of Bias

This was a single-arm, open-label trial with no placebo comparator. Open-label design introduces performance bias, and the absence of a randomized control arm means we cannot calculate a true between-group effect size for testosterone normalization. By GRADE standards, this design begins at Low certainty (observational/single-arm) but can be upgraded if the effect size is large (the responder rate of 87% qualifies as large) and if dose-response relationships are consistent. Applying those upgrade criteria, the certainty for the primary endpoint reaches Moderate [2].

GRADE Domain Analysis: Inconsistency

A second FDA registration study (Study II) using a comparable protocol produced consistent results, with 95% of subjects achieving Cavg in the normal range during the pharmacokinetic assessment period. This cross-study consistency reduces the inconsistency concern and supports a Moderate certainty rating rather than downgrading to Low.

GRADE Domain Analysis: Indirectness

The population studied was predominantly White men aged 18 to 75 with classic hypogonadism symptoms and laboratory confirmation. Generalizability to men with late-onset hypogonadism without clear organic etiology, or to men from more diverse ethnic backgrounds, remains uncertain. The Endocrine Society 2018 Clinical Practice Guideline on male hypogonadism notes: "We recommend against making a diagnosis of androgen deficiency in men with acute or subacute illness" [3], which highlights how trial populations often exclude the most clinically ambiguous cases.

GRADE Domain Analysis: Imprecision

The confidence interval for the 87% responder rate, based on N=166 with approximately 123 evaluable at day 90, is relatively wide. This contributes one minor downgrade toward Moderate certainty. A larger confirmatory trial with pre-specified statistical thresholds and a randomized design would be needed to reach High certainty.

Blood Pressure: The Boxed Warning and Its Evidence

Jatenzo carries a boxed warning for blood pressure increases. This is not a class-wide testosterone warning; it is specific to Jatenzo based on data from the Swerdloff trial showing a mean increase in systolic blood pressure of 3.5 mmHg and diastolic blood pressure of 2 mmHg from baseline at week 52 [1]. Across the trial population, 16% of subjects required new or intensified antihypertensive therapy.

GRADE Certainty for the BP Signal: Moderate

The BP finding was based on serial measurements in a controlled trial setting and was consistent across both registration studies. It meets criteria for Moderate certainty: the signal is real and reproducible, but the long-term cardiovascular outcome implications (myocardial infarction, stroke, major adverse cardiovascular events) are not yet quantified from dedicated outcomes trials.

Clinical Implication of the BP Data

The FDA label states that Jatenzo is contraindicated in men with uncontrolled hypertension. This is a harder contraindication than the class labeling for gels or injectables, which generally carry only a precaution. Clinicians prescribing Jatenzo should obtain baseline blood pressure, recheck at three months (coinciding with the first pharmacokinetic assessment), and annually thereafter. The American Heart Association defines Stage 1 hypertension as systolic 130 to 139 mmHg or diastolic 80 to 89 mmHg [4]; men at or above these thresholds at baseline warrant careful risk-benefit discussion before starting Jatenzo.

Pharmacokinetics Graded by Evidence Quality

Absorption and Food Effect

Jatenzo must be taken with food containing at least 15 grams of fat. Without food, testosterone absorption drops by approximately 40%, a finding supported by dedicated pharmacokinetic sub-studies within the Swerdloff trial [1]. This food dependency is clinically significant: a patient who skips breakfast and takes his morning dose will likely be undertreated that day.

Dose Titration Protocol

The FDA-approved titration scheme starts all patients at 237 mg twice daily. After a pharmacokinetic assessment at day 90 (a serum testosterone drawn 3 to 5 hours post-dose plus a pre-dose trough), the prescriber adjusts:

• If Cavg exceeds 1,050 ng/dL, down-titrate.
• If Cavg falls below 300 ng/dL, up-titrate.
• If Cavg is within range, maintain current dose.

This structured titration approach is one of the formulation's strengths. It produces documented Cavg data rather than relying on a single trough measurement, which is the standard monitoring approach for testosterone cypionate injections.

GRADE Certainty for PK Claims: High

Pharmacokinetic parameters (Cavg, Cmax, Tmax) are measured with validated assays under controlled conditions. The PK data from Jatenzo trials carries High certainty by GRADE standards because the outcomes are objective, assay-validated, and internally consistent across studies [1].

Comparative Effectiveness: Jatenzo vs. Other TRT Routes

No head-to-head randomized controlled trial has directly compared Jatenzo to testosterone cypionate, gels, or subcutaneous pellets on patient-reported outcomes, cardiovascular events, or quality of life. This is a significant evidence gap.

The table below summarizes available GRADE certainty ratings by domain and comparator, based on indirect comparisons from systematic reviews:

| Outcome Domain | Jatenzo GRADE | Injectable T Cypionate GRADE | Topical Gel GRADE | |---|---|---|---| | Testosterone normalization | Moderate | Moderate | Moderate | | Sexual function improvement | Low (indirect) | Low | Low | | Bone mineral density | Low | Moderate | Low | | CV safety (long-term) | Low | Low | Low | | Erythrocytosis risk | Low | Low | Low | | Hepatotoxicity risk | Moderate (low signal) | High (very low signal) | High (very low signal) |

The Endocrine Society 2018 guideline states: "We suggest that clinicians consider patient preference, pharmacokinetics, application site reactions, and formulation cost when selecting among testosterone preparations" [3]. This reflects the reality that no preparation has demonstrated superiority on hard clinical endpoints.

Sexual Function and Symptom Evidence

Swerdloff et al. Included the Androgen Deficiency in the Aging Male (ADAM) questionnaire as a secondary endpoint. Total ADAM score improved from a mean of 5.1 positive responses at baseline to 2.8 at week 52, reflecting symptomatic improvement [1]. Low ADAM scores (below 3 positive responses) correlate with restored androgenic status.

GRADE for Symptom Outcomes: Low

Patient-reported symptom measures are susceptible to placebo effect, and this was an open-label trial with no control arm. The absence of blinding is a major source of bias for subjective endpoints. GRADE requires downgrading symptom outcomes to Low certainty in this context. The numerical improvement is clinically plausible and aligns with the testosterone normalization data, but it cannot be cleanly attributed to the drug without a randomized comparator.

Libido and Erectile Function

No dedicated validated erectile function instrument (such as the IIEF-5) was reported as a primary or pre-specified secondary outcome in the key Jatenzo trial. This is a gap. In contrast, the Testosterone Trials (TTrials), a coordinated set of seven double-blind placebo-controlled trials in older hypogonadal men, showed that testosterone gel significantly improved sexual desire and erectile function compared to placebo [5]. TTrials data applies to testosterone as a class but cannot be directly attributed to the oral formulation.

Erythrocytosis and Hematologic Safety

Polycythemia (hematocrit above 54%) occurred in 5.4% of Jatenzo-treated subjects in the Swerdloff trial. This rate is lower than the rates commonly reported with testosterone cypionate at standard injection intervals (some series report rates of 10 to 20% depending on dose and monitoring frequency) [1]. The mechanism is testosterone-driven erythropoiesis via EPO stimulation and direct bone marrow effects.

GRADE for Erythrocytosis Risk: Low

The Swerdloff data is from a single-arm study with 52 weeks of follow-up, which is insufficient to characterize the true incidence rate. Rates depend heavily on baseline hematocrit, dose, and monitoring intensity. Low certainty is appropriate here. The Endocrine Society guideline recommends checking hematocrit at baseline, three months, and annually; withholding therapy if hematocrit exceeds 54% [3].

Bone Mineral Density Evidence

No bone mineral density primary endpoint data from dedicated Jatenzo trials is available. Published evidence on testosterone and BMD relies on class-level data, including TTrials (which reported that testosterone gel increased volumetric BMD at the spine by 7.5% versus placebo over 12 months) [5] and a Cochrane systematic review showing that testosterone therapy modestly improves lumbar spine BMD in hypogonadal men [6].

Extrapolating class-level BMD data to Jatenzo specifically requires assuming equivalent androgenic effect at steady-state Cavg, which the PK data supports but no fracture-outcome trial confirms. GRADE certainty for Jatenzo-specific BMD benefit is Low due to indirectness.

Cardiovascular Safety: The Most Important Evidence Gap

Long-term cardiovascular safety of testosterone therapy remains the most contested area in endocrinology. The TRAVERSE trial (N=5,204), published in 2023 in the New England Journal of Medicine, randomized middle-aged and older hypogonadal men with elevated cardiovascular risk to testosterone gel or placebo over a median follow-up of 33 months. TRAVERSE found no significant difference in major adverse cardiovascular events (MACE) between groups (hazard ratio 0.96, 95% CI 0.78 to 1.17) [7]. This is the most methodologically rigorous CV safety dataset for testosterone therapy to date.

Can TRAVERSE Data Be Applied to Jatenzo?

TRAVERSE enrolled men on topical testosterone gel, not oral testosterone undecanoate. The delivery system, pharmacokinetic profile, and blood pressure effects differ. Jatenzo's specific systolic BP increase of 3.5 mmHg is not trivially extrapolated from gel data. Each 5 mmHg increase in systolic BP is associated with an approximately 7% increase in coronary heart disease risk based on epidemiological meta-analyses [4].

GRADE certainty for long-term MACE safety with Jatenzo specifically: Low. The most reasonable clinical approach is to use TRAVERSE data as context, acknowledge the BP signal from the Jatenzo label, and apply strict hypertension monitoring.

The TESTOSTERONE Trial and Polycythemia Signal

A 2010 trial by Basaria et al. (NEJM) examining testosterone gel in older men with limited mobility was stopped early due to excess cardiovascular events in the testosterone arm [8]. This trial was small (N=209) and confounded, but it reinforced the need for careful patient selection. That signal does not apply directly to Jatenzo but adds to the Low certainty background for oral testosterone CV outcomes.

Guideline Positioning for Jatenzo

The Endocrine Society 2018 Clinical Practice Guideline on male hypogonadism does not rank individual formulations above others for efficacy; it recommends choosing based on patient preference, cost, and side-effect profile [3]. The American Urological Association 2018 guideline similarly lists available formulations without preferentially endorsing any single preparation [9].

The FDA-approved label for Jatenzo explicitly states it is not approved for use in women or in men with age-related hypogonadism without pathological etiology, mirroring guideline caution about treating men with low-normal testosterone who lack clear organic hypogonadism [1].

Summary GRADE Table for Jatenzo

| Clinical Outcome | Certainty | Key Reason for Rating | |---|---|---| | Serum testosterone normalization (Cavg 300 to 1,050 ng/dL) | Moderate | Single-arm trial; large effect size upgrades from Low | | Blood pressure increase | Moderate | Consistent across two trials; no MACE outcome data | | Sexual symptom improvement (ADAM score) | Low | Open-label; subjective; no placebo control | | Erectile function (IIEF) | Very Low | Not assessed in key trial; indirect class data only | | Erythrocytosis incidence | Low | Short follow-up; single-arm; population-dependent | | Bone mineral density | Low | Indirect class data; no Jatenzo-specific BMD trial | | Long-term MACE safety | Low | No dedicated CV outcomes trial for oral TU in US population | | Hepatotoxicity (absence of) | Moderate | Mechanistically supported; no liver enzyme elevations in trial |

Practical Prescribing Considerations Based on Evidence Grade

Prescribers can use Jatenzo with confidence that testosterone normalization will occur in roughly 87% of properly selected, titrated patients. That claim is Moderate certainty.

Prescribers should counsel patients that symptom improvement data is less certain (Low) and that long-term cardiovascular safety specific to this formulation remains uncharacterized. The most defensible use case is a hypogonadal man who wants to avoid injections, cannot use topical gels due to transfer concerns (for example, men with young children at home), and has controlled or normal blood pressure at baseline.

Before initiating Jatenzo, confirm baseline systolic BP is below 130 mmHg. Recheck at the 90-day pharmacokinetic visit. If systolic BP rises above 130 mmHg, initiate lifestyle modification or pharmacotherapy before continuing testosterone treatment.